Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension

O Sitbon, M Humbert, JL Jagot… - European …, 1998 - Eur Respiratory Soc
In a subset of patients with primary pulmonary hypertension (PPH), high doses of oral
calcium-channel blockers (CCB) produce a sustained clinical and haemodynamic improvement. …

Primary pulmonary hypertension associated with the use of fenfluramine derivatives

…, M Fartoukh, O Sitbon, M Humbert, JL Jagot… - Chest, 1998 - Elsevier
Fenfluramine derivatives (Fds) are a well-established risk factor for primary pulmonary
hypertension (PPH). We compared 62 Fd-PPH patients (61 women) evaluated in our center …

The ETHICA study (part I): elderly's thoughts about intensive care unit admission for life-sustaining treatments

…, P Garçon, M Levy-Soussan, JL Jagot… - Intensive care …, 2013 - Springer
J Gerontol B Psychol Sci Soc Sci 57:S348–S354 … , Oye RK, Youngner S, Califf R, Layde
P, Desbiens N, Connors AF Jr, Lynn J (1996) Choices of seriously ill patients about … JL Jagot

Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study

…, O Sanchez, M Fartoukh, JL Jagot… - European …, 1999 - Eur Respiratory Soc
Continuous intravenous epoprostenol improves exercise capacity, haemodynamics, and
survival in severe primary pulmonary hypertension. Pulmonary hypertension can also be life-…

Treatment of severe pulmonary hypertension secondary to connective tissue diseases with continuous IV epoprostenol (prostacyclin)

M Humbert, O Sanchez, M Fartoukh, JL Jagot, O Sitbon… - Chest, 1998 - journal.chestnet.org
MATERIALS AND METHODS Twelve patients with severe pulmonary hypertension secondary
to systemic lupus erythematosous (n= 4), systemic sclerosis (n= 4), mixed CTD (n= 3), and …

Improvement of severe pulmonary hypertension in a patient with SLE.

…, B Wechsler, P Godeau, F Brenot, JL Jagot… - Annals of the …, 1996 - ncbi.nlm.nih.gov
pulmonary hypertension Page 1 Letters to the editor rarely described.9 Hypothyroidism, as
was present in our second patient, has also been described in association with watermelon …

Pleural trichomoniasis due to Trichomonas tenax

…, L Maisonneuve, V Estève, JL Jagot… - Revue des maladies …, 2002 - europepmc.org
Thoracic infections due to Trichomonas species often go unrecognised as they are seldom
described in the literature. We describe a case that, to our knowledge, is the first reported …

Epidemiology and delays in the management of 355 patients with lung cancer

…, M Chebbo, R Sartene, JL Jagot… - Revue des maladies …, 2006 - europepmc.org
Background The epidemiology of patients with lung cancer in a Seine-Saint-Denis hospital
are reported, as well as causes of diagnostic and therapeutic delays in their management.

Épidémiologie et délais de prise en charge de 355 patients atteints de cancer bronchique

…, L Choudat, M Chebbo, R Sartene, JL Jagot… - Revue des maladies …, 2006 - Elsevier
Introduction L’épidémiologie, les délais diagnostiques et thérapeutiques du cancer
bronchique d’un hôpital de Seine-Saint-Denis sont rapportés. Matériel et méthodes Analyse …

Targeted agents in the treatment of lung cancer

…, C Beuzelin, JL Jagot, S Salmeron, J Tredaniel - Pathologie …, 2012 - europepmc.org
Lung cancer is in France, the leading cause of cancer death. Despite the dramatic advances
that have allowed in a few years to go, for metastatic cancer, from a median survival without …